CL2014000759A1 - Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición. - Google Patents

Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.

Info

Publication number
CL2014000759A1
CL2014000759A1 CL2014000759A CL2014000759A CL2014000759A1 CL 2014000759 A1 CL2014000759 A1 CL 2014000759A1 CL 2014000759 A CL2014000759 A CL 2014000759A CL 2014000759 A CL2014000759 A CL 2014000759A CL 2014000759 A1 CL2014000759 A1 CL 2014000759A1
Authority
CL
Chile
Prior art keywords
composition
development
pufa
probiotic
oligosaccharides
Prior art date
Application number
CL2014000759A
Other languages
English (en)
Spanish (es)
Inventor
Clara Garcia-Rodenas
Kurt Ornstein
Original Assignee
Nesctec S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47019022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000759(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nesctec S A filed Critical Nesctec S A
Publication of CL2014000759A1 publication Critical patent/CL2014000759A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pediatric Medicine (AREA)
  • Psychology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014000759A 2011-10-18 2014-03-27 Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición. CL2014000759A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11185600 2011-10-18

Publications (1)

Publication Number Publication Date
CL2014000759A1 true CL2014000759A1 (es) 2014-08-22

Family

ID=47019022

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000759A CL2014000759A1 (es) 2011-10-18 2014-03-27 Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.

Country Status (16)

Country Link
US (1) US20140271562A1 (enExample)
EP (2) EP3095331A1 (enExample)
CN (1) CN103889238B (enExample)
AU (1) AU2012325060B2 (enExample)
BR (1) BR112014008944B1 (enExample)
CL (1) CL2014000759A1 (enExample)
ES (1) ES2601891T3 (enExample)
IN (1) IN2014DN01468A (enExample)
MX (1) MX350435B (enExample)
MY (1) MY170185A (enExample)
PH (1) PH12014500443A1 (enExample)
PL (1) PL2775852T3 (enExample)
PT (1) PT2775852T (enExample)
RU (1) RU2607458C2 (enExample)
WO (1) WO2013057049A1 (enExample)
ZA (1) ZA201403591B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
DK2708147T3 (da) 2012-09-14 2020-05-18 Abbott Lab Fremgangsmåder til forøgelse af hjernefunktionalitet under anvendelse af 2-fucosyl-lactose
EP2708145B1 (en) 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
EP2880993A1 (en) * 2013-12-04 2015-06-10 Abbott Laboratories Method of achieving memory and learning improvement by the administration of sialic acid
US20170000810A1 (en) * 2013-12-19 2017-01-05 Nestec S.A. Nutritional composition to reduce metabolic stress in infants
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
FR3020949B1 (fr) * 2014-05-16 2018-02-09 Ecole Normale Superieure De Lyon Composition permettant de favoriser la croissance juvenile humaine et animale en cas de malnutrition
MY182925A (en) 2014-10-31 2021-02-05 Nestle Sa Composition comprising fut2-dependent oligosaccharides and lacto-n-neotetraose for use in promoting brain development and cognition
WO2016086151A1 (en) * 2014-11-26 2016-06-02 Abbott Laboratories Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic
WO2016145628A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Composition comprising siallyllactose for use in enhancing learning skills and memory function
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
EP3331534B1 (en) * 2015-08-04 2019-12-18 Société des Produits Nestlé S.A. Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants
CN108541221B (zh) 2015-12-15 2023-02-28 格礼卡姆股份公司 Hmo的混合物
MX2018009016A (es) * 2016-01-26 2018-09-28 Nestec Sa Composiciones que comprenden oligosacaridos sialilados para usar en infantes o niños pequeños para prevenir la obesidad mas adelante en la vida o comorbilidades relacionadas y promover un crecimiento sano.
EP3407740A1 (en) * 2016-01-26 2018-12-05 Nestec S.A. COMPOSITIONS COMPRISING 2FL AND LNnT TO CONTROL FOOD INTAKE AND GROWTH IN INFANTS OR YOUNG CHILDREN
JP7088829B2 (ja) * 2016-04-13 2022-06-21 株式会社明治 新生児向けの脳機能改善用組成物
CA3030809A1 (en) 2016-07-28 2018-02-01 Fonterra Co-Operative Group Limited Sialyloligosaccharide product and process
MX2019010742A (es) 2017-05-04 2020-02-13 Univ Leland Stanford Junior Composiciones de alimento y kits promotoras del neurodesarrollo, sistemas y metodos relacionados con las mismas.
AU2018269462B2 (en) 2017-05-16 2024-04-18 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
CN110573030A (zh) * 2017-05-24 2019-12-13 雀巢产品有限公司 用于增强注意力和/或降低冲动的营养组合物
EP3648617A1 (en) * 2017-07-07 2020-05-13 Société des Produits Nestlé S.A. Human milk fortifier
US12628859B2 (en) 2017-07-07 2026-05-19 Societe Des Produits Nestle S.A. Human milk fortifier
RU2698564C1 (ru) * 2019-01-09 2019-08-28 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ прогнозирования риска развития гипотрофии у детей, родившихся в сроке сверхранних преждевременных родов, к скорригированному возрасту 6 месяцев
MX2023005669A (es) 2020-12-04 2023-05-26 Nestle Sa Composicion acuosa estable para promover el crecimiento posnatal temprano en infantes prematuros.
KR102570073B1 (ko) * 2022-11-17 2023-08-24 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용조성물
CN118285505A (zh) * 2024-03-29 2024-07-05 黑龙江飞鹤乳业有限公司 促进大脑发育的营养组合物、食品及配方奶粉
WO2025257135A1 (en) 2024-06-10 2025-12-18 N.V. Nutricia Non-digestible oligosaccharide mixture for infants at risk of brain injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016449A1 (en) 1990-04-16 1991-10-31 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US20040048926A1 (en) * 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
WO2004112507A1 (en) * 2003-06-23 2004-12-29 Nestec S.A. Infant or follow-on formula
CN1863463B (zh) * 2003-06-23 2011-05-04 雀巢技术公司 用于促进肠道屏障成熟的营养组合物
PL1644482T5 (pl) * 2003-06-30 2015-05-29 Clasado Inc Nowa kompozycja galaktooligosacharydów i jej wytwarzanie
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
WO2007090894A1 (en) * 2006-02-10 2007-08-16 Nestec S.A. Oligosaccharide mixture
US9005682B2 (en) * 2006-03-07 2015-04-14 Nestec S.A. Synbiotic mixture
US20080003330A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
CN103005453B (zh) * 2007-11-26 2015-08-19 雀巢产品技术援助有限公司 按年龄配制的婴儿营养系统
EP2417144B1 (en) * 2009-04-07 2017-08-23 Glycom A/S Synthesis of 2'-o-fucosyllactose
EP2251030A1 (en) 2009-05-12 2010-11-17 Nestec S.A. Lactoferrin and brain health and development in infants
EP2258216A1 (en) * 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
EP2258218A1 (en) 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
EP2459202A1 (en) * 2009-07-31 2012-06-06 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
US8993740B2 (en) * 2010-02-19 2015-03-31 Glycom A/S Method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt) containing N-acetyllactosamine
EP2404507A1 (en) 2010-07-08 2012-01-11 Nestec S.A. Array of age-tailored nutritional formula with optimum fat content
BR112013031086A2 (pt) * 2011-06-08 2016-11-29 Nestec Sa composições nutricionais tendo componentes de membrana de glóbulo de gordura de leite exógenos

Also Published As

Publication number Publication date
MX350435B (es) 2017-09-06
WO2013057049A1 (en) 2013-04-25
MY170185A (en) 2019-07-09
CN103889238B (zh) 2017-10-13
CN103889238A (zh) 2014-06-25
PL2775852T3 (pl) 2017-02-28
BR112014008944B1 (pt) 2020-09-15
PT2775852T (pt) 2016-11-08
ES2601891T3 (es) 2017-02-16
RU2607458C2 (ru) 2017-01-10
IN2014DN01468A (enExample) 2015-05-22
AU2012325060A1 (en) 2014-03-13
EP3095331A1 (en) 2016-11-23
MX2014004716A (es) 2015-02-05
BR112014008944A2 (pt) 2017-05-02
EP2775852B1 (en) 2016-08-17
US20140271562A1 (en) 2014-09-18
ZA201403591B (en) 2016-01-27
EP2775852A1 (en) 2014-09-17
PH12014500443A1 (en) 2014-04-14
AU2012325060B2 (en) 2015-11-19
RU2014119844A (ru) 2015-11-27

Similar Documents

Publication Publication Date Title
SMT201600218B (it) Batterio per uso come probiotico per applicazioni nutrizionali e mediche
GB2514951C (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
MX2015002409A (es) Métodos y composiciones para el tratamiento de una afección genética.
CL2014003165A1 (es) Proceso mejorado para la preparación de treprostinil y derivados del mismo.
MX338015B (es) Composiciones que comprenden un componente de estabilidad de la vida util.
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
HRP20190057T1 (hr) Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
WO2014057362A3 (en) Omega -3 compositions
EP2672273A4 (en) INSPECTION SCHIP AND INSPECTION SCHIPE EQUIPPED WITH THE INSPECTION SCHIP
CO7000763A2 (es) Película estructurada que contiene agente beta-nucleante y método para elaborar la misma
CL2014001385A1 (es) Metodo y composicion para aumentar la proporcion de ingredientes dietarios que son resistentes a la degradacion por los microorganismos del rumen
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
BR112014031513A2 (pt) composição alimentícia concentrada, processo para preparar uma composição alimentícia concentrada e uso da composição
BR112014009500A2 (pt) método in vitro para a liberação de um composto de vitamina d, método in vitro para medição de um composto de vitamina d e uso de uma composição reagente
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
MX2013013512A (es) Alimento medico para deterioro cognitivo.
BR112015020849A2 (pt) ésteres de testosterona de cadeia longa lipobalanceados para entrega oral
EP2704697A4 (en) EXTENDED RELEASE PARACETAMOL FORMULATIONS
PL2672985T3 (pl) Bezcytrynianowe kompozycje farmaceutyczne zawierające anakinrę
BR112015014576A2 (pt) cunha de válvula, e método para a fabricação de uma cunha de válvula
UY4067Q (es) Grafica para producto absorbente
EP2879663C0 (fr) Pastilles a cinetiques multiples de liberation de principes actifs
CA145117S (en) Toothbrush packaging